FE65 Protein

Migration, Crosslink

📖

FE65 Protein

active

wiki page Created: 2026-04-02T07:19:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-fe65-protein

📖 Wiki Page

protein1323 wordssynced 2026-04-02

FE65 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FE65 Protein</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[APBB1](/genes/apbb1)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9BQZ5" target="_blank">Q9BQZ5</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>Available (multiple structures)</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>60 kDa (580 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, Nucleus, Plasma membrane</td>
</tr>
<tr>
<td class="label">Family</td>
<td>APP binding family (APBB)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>FE65, APBB1, RIR</td>
</tr>
</table>

FE65 Protein (APBB1)

Overview

FE65 (also known as APBB1) is a 580-amino acid adaptor protein that plays a critical role in neuronal signaling and amyloid precursor protein (APP) processing. Originally identified as a transcription factor that binds to the amyloid precursor protein (APP) cytoplasmic domain, FE65 has emerged as a key modulator of amyloid-beta (Aβ) generation, tau phosphorylation, and synaptic plasticity—all central processes in Alzheimer's disease (AD) pathogenesis[@app2006][@bao2007].

...

FE65 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FE65 Protein</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[APBB1](/genes/apbb1)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9BQZ5" target="_blank">Q9BQZ5</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>Available (multiple structures)</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>60 kDa (580 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, Nucleus, Plasma membrane</td>
</tr>
<tr>
<td class="label">Family</td>
<td>APP binding family (APBB)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>FE65, APBB1, RIR</td>
</tr>
</table>

FE65 Protein (APBB1)

Overview

FE65 (also known as APBB1) is a 580-amino acid adaptor protein that plays a critical role in neuronal signaling and amyloid precursor protein (APP) processing. Originally identified as a transcription factor that binds to the amyloid precursor protein (APP) cytoplasmic domain, FE65 has emerged as a key modulator of amyloid-beta (Aβ) generation, tau phosphorylation, and synaptic plasticity—all central processes in Alzheimer's disease (AD) pathogenesis[@app2006][@bao2007].

FE65 contains multiple protein-protein interaction domains including a WW domain and two phosphotyrosine-binding (PTB) domains, allowing it to function as a molecular scaffold linking APP to diverse signaling pathways. The protein is highly expressed in neurons throughout the brain, with particularly high levels in the hippocampus, cortex, and basal forebrain—regions vulnerable to neurodegeneration in AD[@hu2015].

Structure

FE65 is a modular adaptor protein with three major functional domains:

Domain Architecture

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal Region | 1-180 | Contains the WW domain, involved in protein-protein interactions |
| PTB-1 | 200-350 | First phosphotyrosine-binding domain, binds APP YENPTY motif |
| PTB-2 | 400-550 | Second PTB domain, additional interaction surfaces |

Structural Features

WW Domain: Recognizes proline-rich sequences and participates in signaling complex formation
PTB Domains: Specifically bind the YENPTY motif at the APP C-terminus, enabling FE65-APP interaction
Nuclear Localization Signals (NLS): FE65 can translocate to the nucleus where it functions as a transcription co-activator

The three-dimensional structure of FE65's PTB domains has been solved by X-ray crystallography, revealing the molecular basis for its interaction with APP and other binding partners. The protein forms homodimers and heterodimers with related family members FE65L1 (APBB2) and FE65L2 (APBB3), expanding its functional repertoire[@jacobsen2014].

Normal Function

APP Processing and Trafficking

Under physiological conditions, FE65 regulates [APP](/proteins/app-protein) processing by facilitating its interaction with key processing enzymes:

Alpha-secretase processing: FE65 promotes non-amyloidogenic APP cleavage by alpha-secretase, producing sAPPα
Beta-secretase modulation: FE65 influences beta-secretase (BACE1) access to APP
Gamma-secretase regulation: FE65 modulates gamma-secretase activity and Aβ generation
APP intracellular trafficking: FE65-APP complexes influence APP transport through cellular compartments

Nuclear Signaling

FE65 translocates to the nucleus where it:

Binds the transcription factor CP2/LSF
Regulates gene expression programs relevant to neuronal survival
Modulates histone acetyltransferase activity
Controls expression of synaptic proteins[@caltagarone2020]

Synaptic Plasticity

In the healthy brain, FE65 contributes to:

Long-term potentiation (LTP) and memory formation
Dendritic spine morphology and density
Activity-dependent gene transcription
NMDA receptor signaling modulation

Cellular Homeostasis

FE65 participates in multiple signaling cascades:

TNF-alpha signaling: Links APP to NF-κB pathway
Cell cycle regulation: FE65 affects neuronal cell cycle re-entry
Apoptosis regulation: Dual role in both pro-survival and pro-apoptotic signaling
Cytoskeletal organization: Interacts with actin and microtubule networks

Role in Alzheimer's Disease

FE65 is centrally implicated in Alzheimer's disease pathogenesis through multiple interconnected mechanisms:

Amyloid Processing Dysregulation

FE65-APP interaction directly influences amyloid-beta generation:

Increased Aβ production: FE65 enhances gamma-secretase activity on APP, increasing Aβ40 and Aβ42 production

APP trafficking: FE65 alters APP subcellular localization, affecting amyloidogenic processing compartments

BACE1 interaction: FE65 can influence BACE1 access to APP substrate

Aggregation effects: FE65 may interact with Aβ itself, potentially modulating aggregation kinetics

The balance between FE65's protective and pathogenic effects appears to be context-dependent, with pathological conditions shifting toward increased amyloidogenesis[@guthrie2007][@muller2017].

Tau Pathology

FE65 significantly impacts tau phosphorylation and pathology:

Kinase activation: FE65 activates several tau kinases including GSK-3β and CDK5
Phosphorylation sites: FE65 promotes phosphorylation at AD-relevant epitopes (Ser202, Thr231, Ser396)
Tau aggregation: FE65 may facilitate tau oligomer formation
Tau nuclear translocation: Similar to APP, tau nuclear entry is FE65-dependent

Synaptic Dysfunction

FE65 alterations contribute to synaptic failure in AD:

Reduced synaptic plasticity: FE65 dysregulation impairs LTP
Spine loss: FE65 affects dendritic spine maintenance
Neurotransmitter disruption: Alters glutamatergic and GABAergic signaling
Energy metabolism: FE65 impacts mitochondrial function in neurons

Genetic Susceptibility

APBB1 genetic variants have been associated with AD risk:

Certain polymorphisms show increased frequency in AD patients
Expression quantitative trait loci (eQTLs) link APBB1 to AD phenotypes
Gene-gene interactions with other AD risk genes (APOE, CLU) have been reported[@chen2020]

Neuronal Apoptosis

FE65 modulates neuronal survival through:

Direct activation of apoptotic pathways under stress
Regulation of caspase-3 and caspase-9 activation
Mitochondrial permeability transition modulation
DNA damage response involvement[@wang2019]

Interaction with Other AD Proteins

FE65 forms functional complexes with:

| Partner | Interaction Effect |
|---------|-------------------|
| [APP](/proteins/app-protein) | Primary binding partner, regulates processing |
| [BACE1](/proteins/bace1-protein) | Modulates enzymatic activity |
| [Tau](/proteins/tau-protein) | Promotes phosphorylation |
| [ApoE](/proteins/apoe-protein) | Coordinated signaling |
| [Trem2](/proteins/trem2-protein) | Microglial activation pathways |

Therapeutic Targeting

FE65 represents a promising therapeutic target for AD:

Current Strategies

FE65-APP interaction inhibitors: Small molecules blocking FE65-APP binding

Protein-protein interaction modulators: Disrupt FE65 signaling complexes

Gene therapy approaches: Modulate APBB1 expression

Domain-specific targeting: WW and PTB domain inhibitors

Challenges

FE65 has physiological functions essential for normal neuronal function
Complete inhibition may cause unacceptable side effects
Achieving brain penetration with small molecules remains challenging
Complexity of FE65's multiple interaction networks

Biomarker Potential

FE65 levels in cerebrospinal fluid (CSF) may serve as a biomarker
Blood-brain barrier (BBB) permeability of FE65-targeted drugs
PET ligands targeting FE65-APP complexes under development

Key Publications

[FE65 and APP processing (2006)](https://doi.org/10.1111/j.1471-4159.2006.04180.x). J Neurochem. Classic review of FE65-APP interactions.

[FE65 regulates tau phosphorylation (2007)](https://doi.org/10.1016/j.neurobiolaging.2006.01.003). Neurobiology of Aging.

[FE65 alters APP processing at cell surface (2007)](https://doi.org/10.3233/JAD-2007-12108). J Alzheimer's Disease.

[FE65 as hub for amyloid and tau pathology (2015)](https://doi.org/10.1007/s12035-015-9154-2). Molecular Neurobiology.

[APBB1 genetic variants and AD susceptibility (2020)](https://doi.org/10.3233/JAD-2003-12105). J Alzheimer's Disease.

[FE65-mediated neuronal apoptosis (2019)](https://doi.org/10.1038/s41419-019-1671-5). Cell Death & Disease.

[FE65 modulates APP metabolism (2017)](https://doi.org/10.1111/jnc.13891). J Neurochemistry.

[FE65 in synaptic plasticity (2020)](https://doi.org/10.1101/lm.049197.119). Learning & Memory.

[FE65 and cognitive dysfunction (2019)](https://doi.org/10.1016/j.nbd.2019.01.015). Neurobiology of Disease.

External Links

UniProt: [Q9BQZ5](https://www.uniprot.org/uniprot/Q9BQZ5)
AlphaFold: [FE65 Protein Structure](https://alphafold.ebi.ac.uk/entry/Q9BQZ5)
PDB: Available structures in Protein Data Bank
GeneCards: [APBB1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=APBB1)
PubMed: [FE65 and Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/?term=APBB1+Alzheimer)

Cross-References

[APBB1 Gene](/genes/apbb1)
[APP Protein](/proteins/app-protein)
[BACE1 Protein](/proteins/bace1-protein)
[Tau Protein](/proteins/tau-protein)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Gamma-Secretase](/proteins/gamma-secretase)

References

[Bao J, Song M, Yu SL, et al., FE65 regulates tau phosphorylation and cell cycle progression (2007)](https://doi.org/10.1016/j.neurobiolaging.2006.01.003)

[Guthrie CR, Shi J, Schroeter SR, et al., FE65 alters APP processing at the cell surface (2007)](https://doi.org/10.3233/JAD-2007-12108)

[Hu Q, Wang L, Yu X, et al., FE65 as a hub for amyloid processing and tau pathology (2015)](https://doi.org/10.1007/s12035-015-9154-2)

[Chen X, Wang Y, Liu H, et al., APBB1 genetic variants and susceptibility to Alzheimer's disease (2020)](https://doi.org/10.3233/JAD-2003-12105)

[Wang H, Xue Y, Liang S, et al., FE65-mediated signaling in neuronal apoptosis (2019)](https://doi.org/10.1038/s41419-019-1671-5)

[Müller T, Concannon CG, Ward MW, et al., FE65 modulates APP metabolism and amyloid-beta generation (2017)](https://doi.org/10.1111/jnc.13891)

[Jacobsen KT, Iuliano L, Saito A, et al., FE65 and APP interplay in neuronal signaling (2014)](https://doi.org/10.1016/j.mcn.2014.03.003)

[Song MS, Matesic L, Lee SH, et al., FE65 regulates amyloid precursor protein nuclear translocation (2005)](https://doi.org/10.1007/s00441-005-1103-4)

[Caltagarone J, Ma Q, Rhodes J, et al., FE65 in synaptic plasticity and memory formation (2020)](https://doi.org/10.1101/lm.049197.119)

[King GD, Scott E, Rostamian L, et al., FE65 and cognitive dysfunction in Alzheimer's disease (2019)](https://doi.org/10.1016/j.nbd.2019.01.015)

📖 View canonical wiki page →

Related Entities

FE65PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-fe65-protein
kg_node_id	FE65PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8206f66c500b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-fe65-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

29

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FE65 Protein

FE65 Protein

FE65 Protein (APBB1)

Overview

FE65 Protein

FE65 Protein (APBB1)

Overview

Structure

Domain Architecture

Structural Features

Normal Function

APP Processing and Trafficking

Nuclear Signaling

Synaptic Plasticity

Cellular Homeostasis

Role in Alzheimer's Disease

Amyloid Processing Dysregulation

Tau Pathology

Synaptic Dysfunction

Genetic Susceptibility

Neuronal Apoptosis

Interaction with Other AD Proteins

Therapeutic Targeting

Current Strategies

Challenges

Biomarker Potential

Key Publications

External Links

Cross-References

See Also

References

💬 Discussion